Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

Travelling to Basel, Switzerland for Informa Connect / EBD Group’s BIO-Europe Spring, taking place at the Messe Congress Center between the 20th and 22nd March, pharmaphorum listened to ...

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front ...

Sanofi, one of the world’s largest pharmaceutical companies, has acquired the Serbian biopharmaceutical company Dren Bio for $1.9 billion. Dren Bio is based in San Francisco and was founded by Serbian ...

Wall Street's major averages closed in the green on Friday, and the benchmark S&P 500 (SP500) snapped a four-week losing streak after U.S. President Donald Trump said there might be some "flexibility" ...

Crises continue overseas: UNICEF faces a shortfall in lifesaving food aid for malnourished children in Nigeria and Ethiopia, while Europol dismantled a multimillion euro hearing aid scam in France.

Sanofi is acquiring private biotech, Dren Bio’s targeted bispecific myeloid cell engager (MCE), DR-0201 for an upfront payment of $600 million. In clinical studies, DR-0201 has shown robust B ...